MOTS-c Protocol Research — Lee 2015 Cell Metabolism Dose Range and Vial Math
MOTS-c is the headline mitochondrial-derived peptide — a 16-amino-acid sequence encoded inside the 12S rRNA region of the mitochondrial genome itself. It's the first peptide ever found to be encoded by mitochondrial DNA, and the 2015 Cell Metabolism paper from the Lee lab at USC put it on the metabolic-research map. For UAE researchers running mitochondrial or longevity-orientated protocols, MOTS-c sits in a small group of peptides with both clear mechanism (AMPK pathway activation) and reproducible animal-model dose data.
1. What MOTS-c actually is
MOTS-c (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR). It was identified in 2015 by Changhan David Lee's group at the USC Leonard Davis School of Gerontology and reported in Cell Metabolism. The discovery is genuinely unusual: MOTS-c is encoded inside the mitochondrial 12S rRNA region — meaning mitochondria, long thought to encode only structural and respiratory-chain proteins, also produce a signalling peptide that exits the mitochondrion and acts on the rest of the cell.
The peptide signals through AMPK (AMP-activated protein kinase), the master energy-status sensor that's also activated by exercise, caloric restriction, and metformin. The result is a metabolic-shift cascade: improved glucose handling, increased fatty-acid oxidation, and enhanced insulin sensitivity in animal models. That AMPK-pathway overlap is why MOTS-c earned the "exercise mimetic peptide" label.
2. The Lee 2015 dose record
The original Lee 2015 Cell Metabolism paper used mice. The headline dose was 0.5 mg/kg/day intraperitoneal, dosed over multi-week windows. Key endpoints reported:
| Endpoint | Model | Result |
|---|---|---|
| Insulin sensitivity | HFD-fed mouse | Restored to chow-fed baseline |
| Glucose tolerance | HFD-fed mouse | Improved vs vehicle control |
| Body weight gain | HFD-fed mouse | Attenuated |
| Skeletal muscle AMPK activation | Mouse | Upregulated phosphorylation |
| Hepatic insulin signalling | Mouse | Enhanced |
Allometric scaling from mouse to human-equivalent dose using the FDA conversion factor (mouse: divide by 12.3) gives a research-equivalent dose of roughly 0.04 mg/kg/day. For a 70 kg researcher dose calculation, that's ~2.8 mg/day. Current research-protocol practice cited in the published longevity-research literature uses the 3-10 mg/day range, sometimes administered intermittently (3 days/week) rather than daily.
3. The 10 mg vial — reconstitution math
REVIVE LAB UAE stocks MOTS-c in 10 mg lyophilised vials. The vial yields enough peptide for roughly 3 weeks of daily 3 mg dosing, or 10 doses at 1 mg, or single 10 mg loading-dose protocols. Reconstitution math:
| Bac water added | Concentration | Volume for 1 mg | Volume for 3 mg | Volume for 5 mg |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.1 mL (10 units U-100) | 0.3 mL (30 units) | 0.5 mL (50 units) |
| 2 mL | 5 mg/mL | 0.2 mL (20 units) | 0.6 mL (60 units) | 1.0 mL (100 units) |
| 3 mL | 3.33 mg/mL | 0.3 mL (30 units) | 0.9 mL (90 units) | 1.5 mL (150 units) |
4. AMPK pathway — why MOTS-c gets called an exercise mimetic
The AMPK signalling pathway is activated when cellular energy charge drops — low ATP, high AMP. The canonical activators are exercise (muscle contraction depletes ATP), caloric restriction, and metformin. Lee 2015 showed that exogenous MOTS-c administration upregulates AMPK phosphorylation in skeletal muscle, hepatic tissue, and adipose, producing a coordinated metabolic shift similar to the exercise-training adaptation.
The "mimetic" framing has limits worth flagging. MOTS-c doesn't produce muscle hypertrophy, doesn't drive cardiovascular adaptation, doesn't build mitochondrial density via the contractile-stimulus pathway. It activates the metabolic-signalling endpoint of exercise without the upstream mechanical work. For researchers studying metabolic syndromes, insulin resistance, or aged-tissue mitochondrial dysfunction, that's a useful tool; for researchers interested in performance adaptations, it's an incomplete one.
5. MOTS-c in the longevity stack context
MOTS-c is one of three peptide-based approaches in the published mitochondrial-longevity research literature. The other two are NAD+ precursors (NMN, NR) which act upstream of sirtuin signalling, and SS-31 (elamipretide) which stabilises cardiolipin in mitochondrial membranes. The three address different parts of the same biology:
| Peptide | Mechanism | Target | Route |
|---|---|---|---|
| MOTS-c | AMPK pathway activation | Metabolic signalling | SC injection |
| NAD+ / NMN / NR | Coenzyme + sirtuin substrate | NAD+ pool · sirtuin activity | Injection / oral |
| SS-31 (elamipretide) | Cardiolipin stabilisation | Inner mitochondrial membrane | SC injection |
For researchers building a longevity-orientated stack, MOTS-c + NAD+ covers the signalling and substrate axes; adding Tesamorelin into the protocol introduces a GH/IGF-1 axis layer that overlaps with body-composition outcomes. We cover the comparison in NAD+ vs NMN vs NR and the three-molecule stack rationale in the longevity-stack research overview.
6. Storage — lyophilised vs reconstituted MOTS-c
The lyophilised peptide is highly stable. Refrigerated at 2-8 °C, MOTS-c vials are rated 24+ months. They tolerate room-temperature shipping windows of up to 48 hours, which covers the entire UAE same-day delivery envelope from REVIVE LAB. Once reconstituted:
- Refrigerated (2-8 °C): 28-day stability window for reconstituted MOTS-c, consistent with the broader peptide stability literature.
- Room temperature: Not recommended — bac water provides bacteriostatic protection, not thermal stability for the peptide.
- Freezer: Possible but single-thaw only. Freeze-thaw cycles damage peptide integrity.
- UAE summer specific: Ambient outdoor temperatures of 45 °C+ from June-September exceed the safe handling envelope for the reconstituted form. Move vials directly to refrigeration on arrival.
See UAE peptide cold-chain shipping for the full thermal-stability decision matrix REVIVE LAB ships to.
7. The endpoints MOTS-c research has and hasn't demonstrated
The published evidence base is animal-dominant. Human data is limited and biomarker-orientated rather than clinical-outcome orientated. What's been demonstrated in the literature:
- Yes: AMPK pathway activation, glucose tolerance improvement, insulin sensitivity restoration, attenuated body-weight gain on HFD — all in mouse models.
- Yes: Circulating MOTS-c levels decline with age in humans (observational); higher endogenous MOTS-c associates with lower insulin resistance markers.
- Limited: No published RCT comparing exogenous MOTS-c with placebo for hard clinical endpoints. Human safety database is small.
- Unknown: Long-term (>1 year) administration data, interactions with other peptide stacks, optimal dosing frequency.
8. UAE supply context
UAE peptide researchers ordering MOTS-c face a quality-control question: the peptide is a relatively complex 16-amino-acid sequence, and synthesis purity matters. REVIVE LAB UAE supplies HPLC-verified MOTS-c with batch-level certificate of analysis. The 10 mg vial covers most common research protocols; same-day Dubai dispatch on orders before 3 PM, 24-hour delivery across Dubai/Abu Dhabi/Sharjah/Ajman, 24-48 hours to Al Ain/RAK/Fujairah. Order via MOTS-c UAE.
9. The summary
- MOTS-c is a 16-aa mitochondrial-derived peptide that activates AMPK signalling — the "exercise mimetic" framing comes from this pathway overlap.
- Lee 2015 Cell Metab dose: 0.5 mg/kg/day IP in mice. Allometrically scaled research-equivalent: ~3 mg/day for a 70 kg adult researcher dose calculation.
- 10 mg vial + 2 mL bac water = 5 mg/mL. For 3 mg dose: 60 units on a U-100 syringe.
- Refrigerate reconstituted vials at 2-8 °C, use within 28 days. UAE summer ambient requires immediate refrigeration on arrival.
- Available as MOTS-c UAE via REVIVE LAB in HPLC-verified 10 mg vials with lot-level COA.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed
- Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. PubMed
- Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PubMed
- Karaa A, Haas R, Goldstein A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909-918. PubMed